Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Xoma Royalty Corporation (NQ: XOMA ) 28.76 +0.51 (+1.81%) Streaming Delayed Price Updated: 12:45 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Xoma Royalty Corporation < Previous 1 2 3 Next > XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024 August 13, 2024 XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities August 13, 2024 From XOMA Corporation Via GlobeNewswire FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base July 09, 2024 FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. Via Benzinga Exposures Product Safety Demystifying XOMA: Insights From 5 Analyst Reviews July 09, 2024 Via Benzinga XOMA Declares Quarterly Preferred Stock Dividends June 20, 2024 From XOMA Corporation Via GlobeNewswire Peeling Back The Layers: Exploring XOMA Through Analyst Insights May 31, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For XOMA April 29, 2024 Via Benzinga XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher June 12, 2024 From XOMA Corporation Via GlobeNewswire 3 Crazy Good Stocks to Buy With $500 Right Now June 12, 2024 For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. Via InvestorPlace XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ May 14, 2024 From XOMA Corporation Via GlobeNewswire XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 May 09, 2024 XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. Via InvestorPlace Recap: XOMA Q4 Earnings March 08, 2024 Via Benzinga XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities May 09, 2024 From XOMA Corporation Via GlobeNewswire XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% April 30, 2024 From XOMA Corporation Via GlobeNewswire XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) April 25, 2024 From XOMA Corporation Via GlobeNewswire XOMA Corporation Announces Closing of Tender Offer April 03, 2024 Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right From XOMA Corporation Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE) March 25, 2024 From Brodsky & Smith LLC Via GlobeNewswire XOMA Declares Quarterly Preferred Stock Dividends March 21, 2024 From XOMA Corporation Via GlobeNewswire XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. March 19, 2024 Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio From XOMA Corporation Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – March 19, 2024 From Brodsky & Smith LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB) March 13, 2024 From Brodsky & Smith LLC Via GlobeNewswire XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 March 08, 2024 XOMA stock results show that XOMA missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. Via InvestorPlace XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value March 08, 2024 From XOMA Corporation Via GlobeNewswire XOMA to Present at Upcoming Investor Conferences in March February 28, 2024 From XOMA Corporation Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB) February 20, 2024 From Brodsky & Smith LLC Via GlobeNewswire Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma February 16, 2024 XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024. Via Benzinga XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right February 16, 2024 Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio From XOMA Corporation Via GlobeNewswire XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition January 18, 2024 From XOMA Corporation Via GlobeNewswire FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx January 11, 2024 FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024 From XOMA Corporation Via GlobeNewswire XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors January 08, 2024 From XOMA Corporation Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.